Structural identification of bitespiramycin metabolites in rat: A single oral dose study

Xenobiotica

Volumn 35, Issue 4, 2005, Pages 343-358

  Shi, X G ^a   Fawcett, J P ^b   Chen, X Y ^a   Zhong, D F ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Aldehyde reduction; Bitespiramycin metabolism; Cysteine conjugation; Hydrolyses; Lactone ring opening; Sugar loss

Indexed keywords

4'' (3 METHYLBUTANOATE) DERIVATIVE; ALDEHYDE; BITESPIRAMYCIN; CYSTEINE; DRUG METABOLITE; FOROSAMINE; ISOVALERIC ACID; LACTONE; MYCAROSE; SPIRAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BIOTRANSFORMATION; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG METABOLISM; DRUG MIXTURE; DRUG STRUCTURE; FECES ANALYSIS; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; RAT; REDUCTION KINETICS; SINGLE DRUG DOSE; URINALYSIS; XENOBIOTIC METABOLISM;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; MALE; RATS; RATS, WISTAR; SPIRAMYCIN;

EID: 20944446209     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250500087580     Document Type: Article

References (15)

1. Inoue A, Deguchi T. 1982. The pharmacokinetic studies on spiramycin and acetylspiramycin. Japanese Journal of Antibiotics 35:1998-2004.
2. Kernbaum S. 1985. Susceptibility of mycoplasmas and chlamydiae to macrolides. Journal of Antimicrobial Chemotherapy 16 (Supplement A): 199-200.
3. Mourier P, Brun A. 1997. Study of the metabolism of spiramycin in pig liver. Journal of Chromatography B 704:197-205.
4. Rakhit S, Singh K. 1974. Structure-activity relationship in sixteen membered macrolide antibiotics. Journal of Antibiotics (Tokyo) 27:221-224.
5. Ramu K, Shringarpure S, Williamson JS. 1995. A solution conformation analysis of forocidins I and isoforocidins I using NMR and molecular modeling. Pharmaceutical Research 12:621-629.
6. Rocha RT, Awad CE, Ali A, Matyas R, Vital AC, Silva CO. 1999. Comparison of spiramycin and clarithromycin for community-acquired lower respiratory tract infections. International Journal of Clinical Practice 53:433-436.
7. Rubinstein E, Keller N. 1998. Spiramycin renaissance. Journal of Antimicrobial Chemotherapy 42:572-576.
8. Shang GD, Dai JL, Wang YG. 1999. Construction and physiological studies on a stable bioengineered strain of shengjimycin. Journal of Antibiotics (Tokyo) 54:66-73.
9. Shi XG, Sun YM, Zhang YF, Zhong DF. 2004a. Tissue distribution of bitespiramycin and spiramycin in rats. Acta Pharmacologica Sinica 25:1396-1401.
10. Shi XG, Zhang SQ, Fawcett JP, Zhong DF. 2004b. Acid catalysed degradation of some spiramycin derivatives found in the antibiotic bitespiramycin. Journal of Pharmaceutical and Biomedical Analysis 36:593-600.
11. Shi XG, Zhong DF, Sun L. 2003. Pharmacokinetics of a novel antibiotic bitespiramycin in rats. Asian Journal of Drug Metabolism and Pharmacokinetics 3:134-137.
12. Van Setten DC, Ten Hove GJ, Wiertz EJ, Kamerling JP, Van de Werken G. 1998. Multiple-stage tandem mass spectrometry for structural characterization of saponins. Analytical Chemistry 70:4401-4409.
13. Yamazaki H, Hiroki S, Urano T, Inoue K, Shimada T. 1996. Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes. Xenobiotica 26: 1143-1153.
14. Zhong DF, Shi XG, Sun L, Chen XY. 2003. Determination of three major components of bitespiramycin and their major active metabolites in rat plasma by liquid chromatography-ion trap mass spectrometry. Journal of Chromatography B 791:45-53.
15. Zweers-Zeilmaker WM, Van Miert AS, Horbach GJ, Witkamp RF. 1999. In vitro complex formation and inhibition of hepatic cytochrome P450 activity by different macrolides and tiamulin in goats and cattle. Research in Veterinary Science 66:51-55.